Table 1.
Demographic, biopsy, and laboratory characteristics of patients with proliferative (Class III or IV) or non-proliferative LN.
| Variable | Class II or V (N=8) | Class III or IV (N=25) | P-value |
|---|---|---|---|
| Sex (% female) | 75.0 | 80.0 | 0.76 |
| Race (% black) | 100.0 | 72.0 | 0.09 |
| Age: median (IQR) | 36 (26–44) | 27 (23–36) | 0.27 |
| ISN/RPS Active lesions (%) | 0 | 96 | <0.0001 |
| ISN/RPS Chronic lesions (%) | 12 | 52 | 0.10 |
| ISN/RPS Global lesions (%) | 0 | 8 | 1.0 |
| ISN/RPS Segmental lesions (%) | 38 | 92 | 0.004 |
| NIH Chronicity Score: median (IQR) | 4.5 (0.3–7.8) | 2.0 (1.0–3.5) | 0.47 |
| NIH Activity Score: median (IQR) | 1.0 (1.0–1.8) | 7.0 (5.0–9.0) | 0.0003 |
| Interstitial Fibrosis (%) | 80 | 55 | 0.59 |
| Interstitial Inflammation (%) | 20 | 70 | 0.12 |
| Urine Protein/Creatinine: median (IQR) | 1.3 (0.8–2.9) | 1.9 (0.7–4.6) | 0.66 |
| Serum dsDNA Antibodies (% positive) | 50 | 92 | 0.02 |
| Serum C3: median (IQR) | 77.6 (64.4–95.1) | 48.6 (34.3–70.4) | 0.03 |
| Serum C4: median (IQR) | 14.4 (11.2–26.8) | 9.9 (9.9–15.1) | 0.08 |
| Serum Creatinine: median (IQR) | 1.1 (0.8–2.6) | 0.9 (0.8–1.9) | 0.49 |
| Prednisone (mg/day): median (IQR) | 20 (4–35) | 30 (5.5–60) | 0.58 |